THC Therapeutics(THCT)
$0.00+0.00 (+75.00%)
THCT
THC Therapeutics financials statements
$0.00
At close:+0.00 (+75.00%)
THC Therapeutics (THCT) Ratios
33 Followers
THC Therapeutics Ratios
THCT's free cash flow for Q3 2024 was $-137.06K. For the 2024 fiscal year, THCT's free cash flow was increased by $0.00 and operating cash flow was $-137.06K. See a summary of the company’s cash flow.
| Ratios | Jul 23 | Jul 22 | Jul 21 | Jul 20 | Jul 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.01 | 0.11 | 0.02 | 0.36 |
| Quick Ratio | 0.00 | 0.01 | 0.11 | 0.02 | 0.36 |
| Cash Ratio | 0.00 | 0.00 | 0.10 | 0.02 | 0.25 |
| Solvency Ratio | -0.12 | -0.45 | -0.63 | -1.02 | -18.58 |
| Operating Cash Flow Ratio | -0.03 | -0.13 | -0.14 | -0.32 | -0.26 |
| Short-Term Operating Cash Flow Coverage | -0.11 | -0.52 | -0.45 | -1.37 | -1.86 |
| Net Current Asset Value | $ -3.32M | $ -3.28M | $ -2.66M | $ -1.82M | $ -811.63K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 60.93 | 3.87 | 1.59 | 5.04 | 0.34 |
| Debt-to-Equity Ratio | -0.24 | -0.26 | -0.31 | -0.24 | -0.24 |
| Debt-to-Capital Ratio | -0.31 | -0.35 | -0.44 | -0.32 | -0.31 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.07 | -0.19 | -0.05 | -0.69 |
| Debt Service Coverage Ratio | -0.57 | -1.92 | -0.66 | -2.02 | -51.00 |
| Interest Coverage Ratio | -6.21 | -17.39 | -1.70 | -2.70 | -87.92 |
| Debt to Market Cap | 1125.82 | 78.27 | 47.43 | 51.96 | 0.71 |
| Interest Debt Per Share | 0.03 | 0.03 | 0.06 | 0.06 | 0.04 |
| Net Debt to EBITDA | -1.61 | -0.46 | -0.50 | -0.28 | 0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 101.30% |
| EBT Per EBIT | 78.36% | 86.99% | 200.58% | 146.02% | 87.33% |
| Return on Assets (ROA) | -2979.49% | -734.13% | -392.75% | -2255.73% | -4540.32% |
| Return on Equity (ROE) | 11.69% | 48.84% | 76.11% | 108.24% | 3150.58% |
| Return on Capital Employed (ROCE) | 15.39% | 58.01% | 39.54% | 74.12% | 3561.48% |
| Return on Invested Capital (ROIC) | 20.42% | 79.04% | 61.85% | 97.76% | 4667.27% |
| Return on Tangible Assets | -39493.47% | -784.98% | -406.51% | -2976.24% | -4770.37% |
| Earnings Yield | -55056.01% | -14841.25% | -10426.83% | -23263.13% | -9431.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.01 | 0.02 | 0.04 | 0.16 |
| Inventory Turnover | 0.00 | 493.36 | 19.72 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -507446.16 | -46776.58 | -21619.39 | -10366.21 | -2266.93 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.74 | 18.51 | 0.00 | 0.00 |
| Days of Payables Outstanding | 507446.16 | 46777.32 | 21637.90 | 10366.21 | 2266.93 |
| Operating Cycle | 0.00 | 0.74 | 18.51 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.04 | -0.02 |
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.04 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -139639.00 | -129492.33 | 0.00 | -275.99 |
| Capital Expenditure Coverage Ratio | 0.00 | -139639.00 | -129492.33 | 0.00 | -275.99 |
| Operating Cash Flow Coverage Ratio | -0.11 | -0.52 | -0.51 | -1.37 | -1.86 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -12152.45% | -4093.18% | -2148.34% | -7104.36% | -132.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.00 | -0.01 | -0.01 | -0.00 | -0.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.00 | -0.00 | -0.01 | -0.00 | -0.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.01 | -0.02 | -0.05 | -0.01 | -0.76 |
| Price-to-Operating Cash Flow Ratio | -0.01 | -0.02 | -0.05 | -0.01 | -0.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Enterprise Value Multiple | -1.61 | -0.47 | -0.52 | -0.29 | -0.00 |
| Enterprise Value | 792.13K | 811.23K | 483.30K | 395.08K | 110.34K |
| EV to EBITDA | -1.61 | -0.47 | -0.52 | -0.29 | -0.00 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -9.27 | -1.94 | -1.24 | -0.67 | -0.33 |
| EV to Operating Cash Flow | -9.27 | -1.94 | -1.24 | -0.67 | -0.33 |
| Tangible Book Value Per Share | -0.10 | -0.09 | -0.11 | -0.11 | -0.06 |
| Shareholders’ Equity Per Share | -0.10 | -0.09 | -0.10 | -0.11 | -0.06 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.25 | -0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.05 | -0.08 | -0.12 | -1.77 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 0.78 | 0.87 | 2.01 | 1.38 | 0.96 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.22 | 0.28 | 0.21 | 0.31 | 0.01 |
Currency in USD
